NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT01652976 2021-01-05
FOLFOX-D
University of Florida
Phase 2 Completed
NCT01234935 2018-01-09
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Translational Oncology Research International
Phase 2 Completed
NCT01395017 2016-04-08
LAPC
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2 Completed
NCT00544908 2015-10-05
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT00474812 2015-05-05
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed